Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
Matthew J. Ellis(Guardant (United States)), José Baselga(Novartis (Switzerland)), Kelly K. Hunt(The University of Texas MD Anderson Cancer Center), Jeremy Hoog(Washington University in St. Louis), Katherine DeSchryver(Washington University in St. Louis), Weihua Liu(Chongqing University), Sherri R. Davies(Washington University in St. Louis), Humphrey Gardner(Scripps Research Institute), Semiglazov Vf(Institute of Oncology NN Petrov), Jutta Steinseifer(Novartis (Switzerland)), Lin Li(Shanghai Jiao Tong University), Tao Yu(Weifang Medical University), Robert J. Crowder(University of Rochester), Jacqueline Snider(Washington University in St. Louis), Raj Bandaru(Novartis (United States)), Dean B. Evans(Novartis (Switzerland)), John A. Olson(Vanderbilt University), Mark A. Watson(Washington University in St. Louis)
Cited by 132
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k